Rare disease in Malaysia: Challenges and solutions.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
06
2019
accepted:
10
03
2020
entrez:
3
4
2020
pubmed:
3
4
2020
medline:
17
7
2020
Statut:
epublish
Résumé
Rare diseases are often underdiagnosed, and their management is frequently complicated by a lack of access to treatment and information about the diseases. To allow for better policy planning, we sought to examine the current status of managing rare diseases in Malaysia. This study was conducted in two phases. In the first phase, we triangulated information from reviews of journal publications, documents from the Malaysian government and in-depth interviews among selected key healthcare stakeholders in Malaysia. The second phase was designed as a cross-sectional survey to estimate the number of cases and treatment coverage for rare diseases in Malaysia. Malaysia has no official definition of rare disease yet but currently in the process of reviewing them for Malaysia. There are 13 rare disease specialists and a dozen medical doctors in genetic clinics around Malaysia, mainly in public health facilities. From the survey, 1,249 patients were diagnosed with rare diseases in public hospitals. Only 60% received their medications or supplements, and the rest continued with symptomatic treatment. Generally, Malaysia has made significant progress in the management of rare diseases, but there are still opportunities for development in critical areas. Ultimately, if all healthcare providers, government, society, and politicians work together to manage rare diseases, we will see an improvement in patient outcomes.
Identifiants
pubmed: 32240232
doi: 10.1371/journal.pone.0230850
pii: PONE-D-19-17740
pmc: PMC7117672
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0230850Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Z Evid Fortbild Qual Gesundhwes. 2014;108(7):397-404
pubmed: 25444298
J Pediatr Endocrinol Metab. 2016 Sep 1;29(9):1031-9
pubmed: 27544719
Clin Chim Acta. 2005 Apr;354(1-2):167-80
pubmed: 15748614
Health Policy. 2012 May;105(2-3):154-64
pubmed: 22464590
J Community Genet. 2018 Jan;9(1):37-50
pubmed: 28733824
Trials. 2017 Nov 22;18(1):556
pubmed: 29166947
Biosci Trends. 2012 Apr;6(2):48-51
pubmed: 22621985
Malays J Med Sci. 2014 Mar;21(2):63-7
pubmed: 24876809
J Genet Couns. 2013 Dec;22(6):911-6
pubmed: 23615969
Orphanet J Rare Dis. 2015 Mar 26;10:35
pubmed: 25887186
Intractable Rare Dis Res. 2012 Nov;1(4):139-43
pubmed: 25343087
Am J Med Genet A. 2010 May;152A(5):1136-56
pubmed: 20425818
Intractable Rare Dis Res. 2012 Feb;1(1):3-9
pubmed: 25343064
BMJ. 2016 Jan 26;532:i244
pubmed: 26813049
Ann Acad Med Singapore. 2008 Dec;37(12 Suppl):66-5
pubmed: 19904455
Mol Genet Metab. 2014 Sep-Oct;113(1-2):53-61
pubmed: 25102806
Lancet Child Adolesc Health. 2018 Aug;2(8):543
pubmed: 30119706